Clinical research
A recent study has highlighted the need for more stringent Phase II trial protocols on the basis that over 80% of candidate oncology treatments that go into Phase III failed to achieve OS goals.
Scientists from Stanford University investigated the effectiveness of an oral tablet flu vaccine called VXA-A1.1 by Vaxart, which uses cellular correlates of protection.
Two weeks after Novartis announced it would sell its nearly one-third voting stake in next-door neighbor Roche, investors are chomping at the bit to find out how that almost $21 billion will be put to work.
Biopharma and life sciences companies from across the globe provide updates. Belgium-based Galapagos NV won European approval for Jyseleca for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
The decision comes after the Phase II MOONSONG trial on the oral antiviral pill AT-527 failed to meet the primary endpoint in October.
After 32 years, gene therapy pioneer Guangping Gao, Ph.D., is finally seeing the fruits of the doctoral thesis research he started in 1989.
Three companies have posted major developments in the field of heart disease therapy.
Respiratory Syncytial Virus has been around for a very long period now. But there was no vaccine yet. But, here’s the first vaccine for RSV to shape the future.
Los Angeles-based ACELYRIN, Inc. announced a quarter-million dollars in Series B financing Tuesday morning, along with a splashy licensing deal.
If bentracimab continues to yield the desired results through the rest of the Phase III study, PhaseBio will be on track to file a Biologics License Application in mid-2022.
PRESS RELEASES
